The effect of probiotics on oesteopenia

Effect of of GeriLact (with dominant strains of Lactobacillus Casei and Bifidobacterium Longum) on Bone Biomarkers and Bone Mineral Index Containing Bone Mineral Content and Bone Mineral Density in Osteopenic Women Under Treatment of Vitamin D and Calcium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015092024103N1

Enrollment

Registered

2016-03-13

Start date

2015-10-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia. Postmenopausal osteoporosis

Interventions

Treatment - Drugs

Intervention 1: Placebo group: 1 capsule per day with the same shape, color , odor and same shrink. Intervention 2: Intervention group: all participants receive 1 probiotic capsule(GeriLact) for 24 we

Placebo group: 1 capsule per day with the same shape, color , odor and same shrink.

Intervention group: all participants receive 1 probiotic capsule(GeriLact) for 24 weeks

Eligibility

Sex/Gender

Female

Age

50 Years to 72 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Menopause women (age between 50-72) with osteopenia based on the WHO definition of osteopenia Exclusion criteria: Any acute or chronic situation of kidney; hepatic diseases; uncontrolled hypertension(based on the history); gastrointestinal disease including crohn's disease; ulcerative colitis; celiac disease; chronic diarrhea; peptic ulcer; deodenum ulcer(based on the history); hypocalcemia(based on the history); osteomalacia(based on the history); rheumatoid arthritis(based on the history) or any drugs which can interfere with calcium or bone metabolism like bisphosphonates; calcitonin; glucocorticoid; smoking and hormone compounds.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bone Mineral Density(BMD). Timepoint: before and after the intervention(24 weeks). Method of measurement: DEXA(Densitometery).	—

Secondary

Measure	Time frame
Bone-specific alkaline phosphatase. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;C-terminal telopeptide of type 1 collagen (CTX). Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Osteocalcin. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Osteoprotegrin. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Receptor activator of nuclear factor kappa-B ligand (RANKL). Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.	—

Measure

Time frame

Bone-specific alkaline phosphatase. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;C-terminal telopeptide of type 1 collagen (CTX). Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Osteocalcin. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Osteoprotegrin. Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.;Receptor activator of nuclear factor kappa-B ligand (RANKL). Timepoint: before and after the intervention(24 weeks). Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSadegh Jafarnejad

Tehran University of Medical Sciences

sjafarnejad@razi.tums.ac.ir+98 21 8895 5975

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026